Literature DB >> 21778275

Juvenile cataract-associated mutation of solute carrier SLC16A12 impairs trafficking of the protein to the plasma membrane.

John J Castorino1, Shannon M Gallagher-Colombo, Alex V Levin, Paul G Fitzgerald, Jessica Polishook, Barbara Kloeckener-Gruissem, Eric Ostertag, Nancy J Philp.   

Abstract

PURPOSE: SLC16A12 encodes an orphan member of the monocarboxylate transporter family, MCT12. A nonsense mutation in SLC16A12 (c.643C>T; p.Q215X) causes juvenile cataract with a dominant inheritance pattern. In the present study, in vitro and in vivo experimental models were used to gain insight into how the SLC16A12 (c.643C>T) mutation leads to cataract formation.
METHODS: MCT12 peptide antibodies were generated and used to examine the expression of MCT12 in the lens using immuno-confocal microscopy. To determine whether loss of Slc16a12 resulted in cataract formation, a Slc16a12 hypomorphic rat generated by transposon insertional mutagenesis was characterized using RT-PCR, slit lamp microscopy and histologic methods. Exogenous expression of MCT12 and MCT12:214Δ, a mimic of the mutant allele, were used to assess protein expression and trafficking.
RESULTS: MCT12 protein was detected in the lens epithelium and secondary fiber cells at postnatal day 1. In the Slc16a12(TKO) rat, complete loss of MCT12 did not result in any detectable ocular phenotype. Exogenous expression of MCT12-GFP and MCT12:214Δ-GFP revealed that the full-length protein was trafficked to the plasma membrane (PM), whereas the truncated protein was retained in the endoplasmic reticulum (ER). When both MCT12 and MCT12:214Δ were coexpressed, to mimic the heterozygous patient genotype, the truncated protein was retained in the ER whereas full-length MCT12 was trafficked to the PM. Furthermore, MCT12 was identified as another MCT isoform that requires CD147 for trafficking to the cell surface.
CONCLUSIONS: These data support a model whereby the SLC16A12 (c.643C>T) mutation causes juvenile cataract by a defect in protein trafficking rather than by haploinsufficiency.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21778275      PMCID: PMC3176021          DOI: 10.1167/iovs.10-6579

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  37 in total

1.  Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters.

Authors:  D K Kim; Y Kanai; A Chairoungdua; H Matsuo; S H Cha; H Endou
Journal:  J Biol Chem       Date:  2001-02-20       Impact factor: 5.157

2.  CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression.

Authors:  P Kirk; M C Wilson; C Heddle; M H Brown; A N Barclay; A P Halestrap
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

3.  Fluorescence resonance energy transfer studies on the interaction between the lactate transporter MCT1 and CD147 provide information on the topology and stoichiometry of the complex in situ.

Authors:  Marieangela C Wilson; David Meredith; Andrew P Halestrap
Journal:  J Biol Chem       Date:  2001-11-21       Impact factor: 5.157

4.  Structure and mechanism of the lactose permease of Escherichia coli.

Authors:  Jeff Abramson; Irina Smirnova; Vladimir Kasho; Gillian Verner; H Ronald Kaback; So Iwata
Journal:  Science       Date:  2003-08-01       Impact factor: 47.728

5.  Basolateral sorting signals regulating tissue-specific polarity of heteromeric monocarboxylate transporters in epithelia.

Authors:  John J Castorino; Sylvie Deborde; Ami Deora; Ryan Schreiner; Shannon M Gallagher-Colombo; Enrique Rodriguez-Boulan; Nancy J Philp
Journal:  Traffic       Date:  2011-02-01       Impact factor: 6.215

6.  Targeted genomic deletion of the lens-specific intermediate filament protein CP49.

Authors:  Azita Alizadeh; John I Clark; Teri Seeberger; John Hess; Tom Blankenship; Andrew Spicer; Paul G FitzGerald
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-12       Impact factor: 4.799

7.  Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/basigin-null mouse.

Authors:  Nancy J Philp; Judith D Ochrietor; Carla Rudoy; Takashi Muramatsu; Paul J Linser
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-03       Impact factor: 4.799

Review 8.  The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond.

Authors:  Andrew P Halestrap; David Meredith
Journal:  Pflugers Arch       Date:  2003-05-09       Impact factor: 3.657

9.  The loop between helix 4 and helix 5 in the monocarboxylate transporter MCT1 is important for substrate selection and protein stability.

Authors:  Sandra Galić; Hans-Peter Schneider; Angelika Bröer; Joachim W Deitmer; Stefan Bröer
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

10.  Polarized expression of monocarboxylate transporters in human retinal pigment epithelium and ARPE-19 cells.

Authors:  Nancy J Philp; Dian Wang; Heeyong Yoon; Leonard M Hjelmeland
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-04       Impact factor: 4.799

View more
  16 in total

Review 1.  Monocarboxylate Transporters: Therapeutic Targets and Prognostic Factors in Disease.

Authors:  R S Jones; M E Morris
Journal:  Clin Pharmacol Ther       Date:  2016-08-22       Impact factor: 6.875

2.  Differential effect of cataract-associated mutations in MAF on transactivation of MAF target genes.

Authors:  Vanita Vanita; Gao Guo; Daljit Singh; Claus-Eric Ott; Peter N Robinson
Journal:  Mol Cell Biochem       Date:  2014-07-27       Impact factor: 3.396

3.  Loss of αB-crystallin function in zebrafish reveals critical roles in the development of the lens and stress resistance of the heart.

Authors:  Sanjay Mishra; Shu-Yu Wu; Alexandra W Fuller; Zhen Wang; Kristie L Rose; Kevin L Schey; Hassane S Mchaourab
Journal:  J Biol Chem       Date:  2017-11-21       Impact factor: 5.157

4.  Mutation in the Monocarboxylate Transporter 12 Gene Affects Guanidinoacetate Excretion but Does Not Cause Glucosuria.

Authors:  Nasser Dhayat; Alexandre Simonin; Manuel Anderegg; Ganesh Pathare; Benjamin P Lüscher; Christine Deisl; Giuseppe Albano; David Mordasini; Matthias A Hediger; Daniel V Surbek; Bruno Vogt; Jörn Oliver Sass; Barbara Kloeckener-Gruissem; Daniel G Fuster
Journal:  J Am Soc Nephrol       Date:  2015-09-16       Impact factor: 10.121

Review 5.  X-linked creatine transporter deficiency: clinical aspects and pathophysiology.

Authors:  Jiddeke M van de Kamp; Grazia M Mancini; Gajja S Salomons
Journal:  J Inherit Metab Dis       Date:  2014-05-01       Impact factor: 4.982

Review 6.  Cultured primary human fetal retinal pigment epithelium (hfRPE) as a model for evaluating RPE metabolism.

Authors:  Jeffrey Adijanto; Nancy J Philp
Journal:  Exp Eye Res       Date:  2014-01-28       Impact factor: 3.467

Review 7.  Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology.

Authors:  Stephen J Fairweather; Nishank Shah; Stefan Brӧer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Mutations in MCT8 in patients with Allan-Herndon-Dudley-syndrome affecting its cellular distribution.

Authors:  Simone Kersseboom; Gert-Jan Kremers; Edith C H Friesema; W Edward Visser; Wim Klootwijk; Robin P Peeters; Theo J Visser
Journal:  Mol Endocrinol       Date:  2013-04-02

Review 9.  Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease.

Authors:  Melanie A Felmlee; Robert S Jones; Vivian Rodriguez-Cruz; Kristin E Follman; Marilyn E Morris
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

10.  The cataract and glucosuria associated monocarboxylate transporter MCT12 is a new creatine transporter.

Authors:  Jeannette Abplanalp; Endre Laczko; Nancy J Philp; John Neidhardt; Jurian Zuercher; Philipp Braun; Daniel F Schorderet; Francis L Munier; François Verrey; Wolfgang Berger; Simone M R Camargo; Barbara Kloeckener-Gruissem
Journal:  Hum Mol Genet       Date:  2013-04-10       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.